Morgan Stanley Athira Pharma, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 5,112 shares of ATHA stock, worth $1,584. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,112

Previous 6,012 14.97%

Holding current value

$1,584

Previous $3,000 66.67%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.28 - $0.59 $252 - $531	-900 Reduced 14.97%	5,112 $1,000
Q4 2024 Feb 14, 2025	SELL	$0.42 - $0.8 $11,760 - $22,400	-28,000 Reduced 82.32%	6,012 $3,000
Q3 2024 May 14, 2025	BUY	$0.42 - $3.43 $4,541 - $37,085	10,812 Added 46.6%	34,012 $15,000
Q3 2024 Nov 14, 2024	BUY	$0.42 - $3.43 $4,541 - $37,085	10,812 Added 46.6%	34,012 $15,000
Q2 2024 May 14, 2025	BUY	$1.92 - $2.71 $33,000 - $46,579	17,188 Added 285.89%	23,200 $61,000
Q2 2024 Oct 17, 2024	SELL	$1.92 - $2.71 $37,054 - $52,300	-19,299 Reduced 45.41%	23,200 $61,000
Q2 2024 Aug 14, 2024	SELL	$1.92 - $2.71 $37,054 - $52,300	-19,299 Reduced 45.41%	23,200 $61,000
Q1 2024 Oct 17, 2024	BUY	$2.24 - $4.15 $43,229 - $80,090	19,299 Added 83.19%	42,499 $116,000
Q1 2024 Aug 16, 2024	SELL	$2.24 - $4.15 $15,823 - $29,315	-7,064 Reduced 14.25%	42,499 $116,000
Q1 2024 May 15, 2024	SELL	$2.24 - $4.15 $15,823 - $29,315	-7,064 Reduced 14.25%	42,499 $116,000
Q4 2023 Aug 16, 2024	BUY	$1.39 - $2.46 $36,644 - $64,852	26,363 Added 113.63%	49,563 $120,000
Q4 2023 Feb 13, 2024	SELL	$1.39 - $2.46 $17,386 - $30,769	-12,508 Reduced 20.15%	49,563 $120,000
Q3 2023 Nov 15, 2023	SELL	$1.9 - $3.16 $98,999 - $164,651	-52,105 Reduced 45.64%	62,071 $125,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $488,994 - $743,851	-207,201 Reduced 64.47%	114,176 $336,000
Q1 2023 May 15, 2023	BUY	$2.26 - $4.22 $374,020 - $698,393	165,496 Added 106.17%	321,377 $803,000
Q4 2022 Feb 14, 2023	SELL	$2.76 - $3.71 $114,310 - $153,657	-41,417 Reduced 20.99%	155,881 $494,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $384,345 - $519,456	131,176 Added 198.38%	197,298 $586,000
Q2 2022 Oct 27, 2022	SELL	$2.74 - $13.43 $7,315 - $35,858	-2,670 Reduced 3.88%	66,122 $202,000
Q2 2022 Aug 15, 2022	SELL	$2.74 - $13.43 $7,315 - $35,858	-2,670 Reduced 3.88%	66,122 $202,000
Q1 2022 Oct 27, 2022	BUY	$8.96 - $13.51 $23,923 - $36,071	2,670 Added 4.04%	68,792 $929,000
Q1 2022 May 13, 2022	SELL	$8.96 - $13.51 $216,177 - $325,955	-24,127 Reduced 25.97%	68,792 $929,000
Q4 2021 Feb 14, 2022	SELL	$9.17 - $16.39 $787,281 - $1.41 Million	-85,854 Reduced 48.02%	92,919 $1.21 Million
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $1.64 Million - $1.98 Million	178,773 New	178,773 $1.68 Million

Others Institutions Holding ATHA

# of Institutions

Shares Held

18.4M

Call Options Held

14.3K

Put Options Held

4.4K

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $11.7M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account